jRCT1020260017招募中不适用
Prospective Observational Study for Identification of Predictive Biomarkers of PSMA-Targeted Radioligand Therapy in Prostate Cancer (PROBE-PSMA study)
未提供0 个研究点目标入组 450 人开始时间: 待定
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- No limit 至 No limit（—）
- 性别
- Male
入选标准
- •Histologically or clinically diagnosed prostate cancer.
- •Planned to initiate PSMA radioligand therapy or other standard systemic therapy.
- •Undergoing blood sampling and imaging assessments as part of routine clinical practice.
- •Able to provide written informed consent.
- •Able to comply with study follow-up.
排除标准
- •Considered unsuitable for study participation by the treating physician.
- •Unable to provide informed consent.
- •Medically unable to undergo blood sampling or study follow-up.
- •Considered unsuitable by the principal investigator for safety or study conduct reasons.
研究者
相似试验
尚未招募
不适用
Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT study)IgG4-Related DiseasejRCT1031250749100
尚未招募
不适用
A single-center prospective observational study to evaluate the safety and efficacy of sentinel lymph node navigation surgery (SNNS) for uterine malignanciesEarly-stage cervical cancer and early-stage endometrial cancerjRCT1030260079196
招募中
不适用
A Multicenter, Prospective Observational Study to Evaluate the Efficacy and Safety of Mosunetuzumab Plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (W-JHS NHL04, SUNMOSTAR)jRCT1071260043300
招募中
不适用
A clinical study evaluating CBD and CBG treatments for nocturia using diagnostic indicators. (A clinical study evaluating CBD and CBG treatments for nocturia using diagnostic indicators.)NocturiajRCT103125081810
已完成
1 期
A SINGLE-CENTER, OPEN-LABEL, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE ITRACONAZOLE, A STRONG CYP3A INHIBITOR, ON THE PHARMACOKINETICS OF A SINGLE 30 MG DOSE OF RO7269162 IN HEALTHY PARTICIPANTS2024-510732-52-00F. Hoffmann-La Roche AG18